These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15494779)

  • 21. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex.
    Papadakis S; Reid RD; Coyle D; Beaton L; Angus D; Oldridge N
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):347-53. PubMed ID: 18525392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rehabilitation of the coronary patient. Secondary prevention. A document of the Working Group on Cardiac Rehabilitation of the Sociedad Española de Cardiología].
    Rev Esp Cardiol; 1995 Oct; 48(10):643-9. PubMed ID: 7481032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute coronary syndromes: cardiac rehabilitation programmes and quality of life.
    Chan DS; Chau JP; Chang AM
    J Adv Nurs; 2005 Mar; 49(6):591-9. PubMed ID: 15737219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and rehabilitation as a means of cost containment: the example of myocardial infarction.
    Luginbuhl WH; Forsyth BR; Hirsch GB; Goodman MR
    J Public Health Policy; 1981 Jun; 2(2):103-15. PubMed ID: 6788801
    [No Abstract]   [Full Text] [Related]  

  • 29. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac rehabilitation--a cost analysis.
    Levin LA; Perk J; Hedbäck B
    J Intern Med; 1991 Nov; 230(5):427-34. PubMed ID: 1940778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II ambulatory cardiac rehabilitation (Cologne model). 3 year results after conclusion of the intervention].
    Bjarnason-Wehrens B; Predel HG; Graf C; Rost R
    MMW Fortschr Med; 2000 Jan; 142(3 Suppl):173-7. PubMed ID: 10783608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DES or BMS in acute myocardial infarction?
    Vlaar PJ; de Smet BJ; Zijlstra F
    Eur Heart J; 2007 Nov; 28(22):2693-4. PubMed ID: 17959622
    [No Abstract]   [Full Text] [Related]  

  • 33. [Organization and medical economic effectiveness of the sanatorium-health resort stage in the system of restorative treatment of ischemic heart disease patients].
    Rybinskaia MG
    Vopr Kurortol Fizioter Lech Fiz Kult; 1979; (6):30-3. PubMed ID: 160668
    [No Abstract]   [Full Text] [Related]  

  • 34. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Heart catheter in stable coronary heart disease. Drugs are equally effective].
    Einecke D
    MMW Fortschr Med; 2007 Apr; 149(15):10, 12. PubMed ID: 17668771
    [No Abstract]   [Full Text] [Related]  

  • 36. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do illness perceptions predict attendance at cardiac rehabilitation and quality of life following myocardial infarction?
    French DP; Lewin RJ; Watson N; Thompson DR
    J Psychosom Res; 2005 Nov; 59(5):315-22. PubMed ID: 16253622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiac rehabilitation deserves higher priority].
    Kemps HM
    Ned Tijdschr Geneeskd; 2012; 156(49):A5778. PubMed ID: 23218042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes analysis with case management.
    Cotham P; Cunningham B; Gilmer C
    J Cardiovasc Manag; 1994; 5(6):23-4, 26-33. PubMed ID: 10139236
    [No Abstract]   [Full Text] [Related]  

  • 40. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.